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Letter to the editorRalstonia pickettii sepsis in a hemodialysis patient from
BulgariaDear Editor,
We report a case of Ralstonia pickettii sepsis in a 75-year
old female patient with chronic kidney failure undergoing
hemodialysis. The patient had a permanent vascular access
for hemodialysis and was febrile for a few days prior to the
sampling for microbiological analysis. She had a fever of
38.8 ◦C, as well as a highly elevated erythrocyte sedimenta-
tion rate (64mm/h), high C-reactive protein (290mg/L), and
high white blood cell count (18,000 cells/L). The antimicro-
bial therapy, which consisted of intravenous ceftriaxone 1g/d,
was initiated two days before taking the samples.
The patient’s blood culture was positive after 24h incu-
bation in the BACTEC 9050 system. Typical pinpoint colonies
were seen on blood agar and small lactose-negative colonies
on McConkey agar. The oxidase test was positive. Gram
staining revealed Gram-negative rods. Bacterial identiﬁca-
tion was done by the BBL Enteric/Nonfermenter ID System
(Becton Dickinson). Antimicrobial susceptibility testing was
performed by the Etest (LIOFILCHEM) according to the Clinical
and Laboratory Standards Institute 2010 recommendations.
The isolate showed a high-level resistance to clinically use-
ful aminoglycosides (amikacin, gentamicin, and tobramycin
– MICs>256g/mL). The strain was susceptible to the fol-
lowing antimicrobials: piperacillin/tazobactam (0.5g/mL),
ceftriaxone (3.0g/mL), ceftazidime (2.0g/mL), cefepime
(1.5g/mL), imipenem (0.25g/mL), meropenem (0.5g/mL),
ciproﬂoxacin (0.064g/mL), levoﬂoxacin (0.064g/mL), and
trimethoprim/sulfamethoxazole (0.25g/mL).
Despite the in vitro evidence of susceptibility to ceftri-
axone, there was no clinical beneﬁt from the administered
treatment, as already described.1 The discrepancy between
the in vitro testing and the in vivo activity of the drug required
a switch to intravenous levoﬂoxacin with a starting dose of
750mg and then 500mg, four times a day. Clinical symptoms
subsided within 36hours.
To ﬁnd the molecular basis of the observed high-level
resistance to aminoglycosides, we assayed for putative 16SrRNA methylase genes. The armA, rmtA, rmtB, rmtC and rmtD
genes were detected by multiplex polymerase chain reac-
tion (PCR) as previously described.2 No 16S rRNA methylase
gene was identiﬁed in the isolate. Enzymatic modiﬁcation is
the other possible mechanism of high-level aminoglycoside
resistance. The genes encoding for aminoglycoside modifying
enzymes (AMEs) are usually found on plasmids and trans-
posons. Most enzyme-mediated aminoglycoside resistance in
Gram-negative bacilli is due to multiple genes. Further studies
on AMEs are needed.
In an attempt to determine the source of R. pickettii sepsis,
an assessment of the microbiological purity of the hemodial-
ysis ﬂuid was carried out. A sample of dialysis ﬂuid was taken
from the septum port in the line between the machine and
the dialyser while simultaneously drawing a blood sample.
This sample was inoculated into a tube of Trypticase soy broth
(Beckton Dickinson) for 24hours at 35 ◦C. Subcultures on blood
agar and McConkey agar media were made. R. pickettii was
again isolated.
The dialysis ﬂuid strainwas compared to that isolated from
patient’s blood by using random ampliﬁed polymorphic DNA
(RAPD) typing. RAPD was performed with Ready-To-Go RAPD
Analysis Beads (GE Healthcare) as previously described.3 Two
R. pickettii strain DNAs revealed identical RAPD proﬁles, each
consisting of four bands (with size ranging from220 to 1600bp)
(Fig. 1). Thus, we successfully identiﬁed the hemodialysis sys-
tem as a source of infection in our patient.
R. pickettii is a relevantly rare isolate that represents a
potential threat for immunocompromised individuals, i.e.
cancer patients, patients with hematological malignancies, or
infants.4–6 It could also contaminate permanent indwelling
intravenousdevices, respiratory care solutions, distilledwater,
water for injection, or hemodialysis systems.7–9In conclusion,
to our knowledge, this is the ﬁrst case of R. pickettii sepsis
described in Bulgaria. The hemodialysis system was identiﬁed
as a source of R. pickettii infection. To prevent hemodialysis-
related infections, it is important to maintain hemodialysis
systems clear of microbial contamination.
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Fig. 1 – Randomly ampliﬁed polymorphic DNA (RAPD) of R.
pickettii isolates generated with RAPD-4 primer
(5′-AAGAGCCCGT-3′). Lanes: M, standard size marker
(100-bp ladder); 1, R. pickettii isolate from the patient’s
blood; 2, R. pickettii isolate from the hemodialysis ﬂuid; K1,
RAPD proﬁle of the reference strain E. coli C1a generated
with RAPD-2 primer; K2, RAPD proﬁle of the reference
strain E. coli BL21 (DE3) generated with RAPD-2 primer
(
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95′-GTTTCGCTCC-3′).
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